B. Braithwaite

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients

R. Clark, R. Salim, J. Clark, 2014, Blood Cancer Journal.

Evaluating the use of plerixafor in stem cell mobilisation – an economic analysis of the PHANTASTIC trial

A. Haycox, R. Clark, A. Martin, 2015, Journal of clinical apheresis.

Plerixafor is cost‐effective compared to conventional chemotherapy for first‐line haematopoietic stem cell mobilization: Data from the PHANTASTIC trial

A. Haycox, R. Clark, A. Martin, 2015 .